Marseille-Oxford Cancer Centres Collaboration (MOC3)


As a result of complementary clinical and scientific expertise in the field of DNA Damage Repair (DDR) the Cancer Research UK Oxford Centre, Institut Paoli-Calmettes and Cancer Research Centre of Marseille have established the Marseille-Oxford Cancer Centres Collaboration (MOC3). The aim of the partnership is to expedite the translation of fundamental scientific DDR expertise into the clinic by developing a series collaborative research projects and training programmes. The group seeks to benefit from the well-aligned state-of the-art expertise and infrastructures of the two sites to tackle major clinical challenges faced by those treating cancer patients.

The first MOCCC Symposium held during October 2018 in Marseille assembled almost 100 scientists representing the DNA Damage Response research community of the two centres including students, clinicians, post-docs and group leaders. A follow-up meeting will take place in Oxford and will be aimed at identifying collaborative projects centred around the DNA damage response and the maintenance of genome stability in relationship to leukemias and pancreatic cancer. In spring 2019 MOC3 will announce the initial series of collaborative projects that they have pump primed, more information about which will be featured on this webpage.

Oxford speakers at the first MOCCC symposium included Peter McHugh, Tim Humphrey, Ester Hammond, Madalena Tarsounas, David Clynes  (Department of Oncology), Dragana Ahel, Fumiko Esashi (Sir William Dunn School of Pathology), David Church, Ross Chapman (Nuffield Department of Medicine), Martin Cohn, Nick Lakin (Department of Biochemistry), Andrew Blackford (MRC Weatherall Institute of Molecular Medicine).

Speakers from the Cancer Research Centre of Marseille were Jean-Paul Borg, Christophe Lachaud, Pierre-Henri Gaillard, Bertrand Llorente, Mauro Modesti, Vincent Géli, Xavier Morelli, Emmanuelle Charaffe-Jauffret, from the Institut Paoli-Calmettes Antony Goncalves, and from the Marseille Immunopole Norbert Vey.